论文部分内容阅读
ＢｉｏＷｏｒｌｄＴｏｄａｙ１９９８年１２月２２日号报道：Ｃａｍｂｒｉｄｇｅ神经科学公司与Ｂａｙｅｒ公司作成了一笔潜在价值为２６００万美元的交易，用于开发重组胶质细胞生长因子２（ＧＧＦ２），该因子用于治疗神经退化性疾病，如多发性硬化症（ＭＳ）。对于Ｃａ...
BioWorldToday December 22, 1998 reported that Cambridge Neuroscience and Bayer have made a $26 million potential transaction to develop recombinant glioblast growth factor 2 (GGF2), a factor used to treat neurodegeneration. Sexual disorders such as multiple sclerosis (MS). For Ca...